Fate Therapeutics Cm (FATE) 1.75 $FATE
Fate's (FATE) ProTmune Gets Fast Track Status, Stock Up
Zacks Equity Research - Zacks Investment Research - Tue Jun 21, 10:46AM CDT
Fate Therapeutics (FATE) announced that the FDA has granted the Fast Track status to its immunotherapy ProTmune.
FATE: 1.75 (-0.02), ANIP: 55.38 (-1.13), RTRX: 18.47 (-0.18), ACOR: 25.57 (-0.64)
Fate Therapeutics (FATE) Catches Eye: Stock Jumps 19.1%
Zacks Equity Research - Zacks Investment Research - Tue Jun 21, 7:25AM CDT
Fate Therapeutics, Inc. (FATE) moved big last session, as its shares jumped over 19% on the day.
FATE: 1.75 (-0.02), NEO: 8.92 (-0.23)
Fate Therapeutics to Host Off-the-Shelf Cancer Immunotherapy Focus Session at 2016 Annual Meeting of International Society for Stem Cell Research
GlobeNewswire - Thu Jun 16, 7:01AM CDT
Fate Therapeutics, Inc. (NASDAQ:FATE), a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that it will host a Focus Session entitled "Fighting Cancer with Off-the-Shelf iPSC Immunotherapies" at the 2016 Annual Meeting of the International Society for Stem Cell Research (ISSCR) on Wednesday, June 22, 2016 from 9:00 a.m. to 12:00 p.m. PT in San Francisco, California.
FATE: 1.75 (-0.02)
Fate Therapeutics Appoints Chris M. Storgard, M.D. as Chief Medical Officer
GlobeNewswire - Tue May 17, 7:01AM CDT
Fate Therapeutics, Inc. (NASDAQ:FATE), a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, today announced that Chris M. Storgard, M.D. has joined the Company as its Chief Medical Officer. Dr. Storgard is an experienced drug development clinician with a proven history of advancing early stage programs through clinical development and product commercialization. As CMO, he will lead the design and execution of the Company's clinical trials for its programmed cellular immunotherapies.
FATE: 1.75 (-0.02)
Fate Therapeutics reports 1Q loss
Automated Insights - Mon May 09, 4:12PM CDT
SAN DIEGO (AP) _ Fate Therapeutics Inc. (FATE) on Monday reported a loss of $8.4 million in its first quarter.
FATE: 1.75 (-0.02)
Fate Therapeutics Reports First Quarter 2016 Financial Results
GlobeNewswire - Mon May 09, 3:01PM CDT
Phase 1/2 Clinical Trial of ProTmune(TM) for Prevention of Acute GvHD and CMV Infection to Begin Enrollment in mid-2016
FATE: 1.75 (-0.02)
Tissue Engineering Market To Reach $11.53 Billion By 2022 Owing To Increased Focus Of Stem Cell Therapies: Grand View Research, Inc.
GlobeNewswire - Thu May 05, 4:00AM CDT
Global tissue engineering market is expected to reach USD 11.53 billion by 2022, according to a new report by Grand View Research, Inc. The demand for tissue engineering is expected to upsurge owing to the shift of focus from stem cell therapies to immunocelluar therapies. Moreover, companies such as Caladrius and Celyad changed their names from Cardio3 Bio NeoStem respectively to reflect their focus on immunotherapies.
FATE: 1.75 (-0.02)
Fate Therapeutics to Webcast Conference Call Reporting First Quarter 2016 Financial Results on May 9, 2016
GlobeNewswire - Mon May 02, 3:01PM CDT
Fate Therapeutics, Inc. (NASDAQ:FATE), a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that the Company will host a conference call and live audio webcast on Monday, May 9, 2016 at 5:00 p.m. ET to report its first quarter 2016 financial results and provide a corporate update.
FATE: 1.75 (-0.02)
Fate Therapeutics (FATE) Jumps: Stock Moves 6.5% Higher
Zacks Equity Research - Zacks Investment Research - Mon Apr 11, 7:15AM CDT
Fate Therapeutics, Inc. (FATE) shares rose almost 7% in the last trading session.
FATE: 1.75 (-0.02), ANIK: 52.79 (-0.51)
Fate Therapeutics to Present at the Needham & Company 15th Annual Healthcare Conference
GlobeNewswire - Tue Apr 05, 3:01PM CDT
Fate Therapeutics, Inc. (NASDAQ:FATE), a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that Scott Wolchko, President and Chief Executive Officer, will be presenting a company overview at the Needham & Company 15th Annual Healthcare Conference in New York City on Tuesday, April 12, 2016 at 4:20 p.m. ET.
FATE: 1.75 (-0.02)
Fate Therapeutics Reports Fourth Quarter and Full Year 2015 Financial Results
GlobeNewswire - Thu Mar 03, 3:01PM CST
ProTmune(TM) Investigational New Drug Application for Prevention of Acute GvHD and CMV Infection Cleared by FDA in January 2016
FATE: 1.75 (-0.02)
Vertex (VRTX) Down on CRL for Kalydeco Label Expansion
Arpita Dutt - Zacks Investment Research - Mon Feb 08, 4:38PM CST
The FDA informed Vertex (VRTX) that its sNDA for expanding the label of its CF treatment, Kalydeco, cannot be approved in its present form.
FATE: 1.75 (-0.02), VRTX: 90.10 (+1.14), LGND: 126.76 (+0.90), CELG: 103.41 (-1.62)
Novo Nordisk Posts In Line Q4 Earnings, Tops Revenues
Zacks Equity Research - Zacks Investment Research - Thu Feb 04, 12:40PM CST
Novo Nordisk (NVO) reported fourth quarter 2015 revenues that increased 2.3% year over year to $4.2 billion beating Zacks Consensus Estimate of $4.1 billion.
FATE: 1.75 (-0.02), NVO: 55.36 (+0.80), ATRA: 22.67 (-0.50), BXLT: 46.02 (-0.18)
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Pipeline Review, H2 2015
M2 - Thu Feb 04, 5:02AM CST
Research and Markets (http://www.researchandmarkets.com/research/trfcb9/acute_lymphocytic) has announced the addition of the "Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Overview - Therapeutics Development - Pipeline Products for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Overview - Pipeline Products for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Comparative Analysis - Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Therapeutics under Development by Companies - Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Therapeutics under Investigation by Universities/Institutes - Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Products under Development by Companies - Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Products under Investigation by Universities/Institutes - Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Companies Involved in Therapeutics Development Companies Mentioned - Partial List - 4SC AG - AbbVie Inc. - Actinium Pharmaceuticals, Inc. - Affimed Therapeutics AG - Altor BioScience Corporation - Amgen Inc. - Atara Biotherapeutics, Inc. - Baxalta Incorporated - Bellicum Pharmaceuticals, Inc. - Bexion Pharmaceuticals, LLC. - Bio-Path Holdings, Inc. - BioSight Ltd. - Bristol-Myers Squibb Company - Calithera Biosciences, Inc. - Cantargia AB - Celator Pharmaceuticals, Inc. - Cellectis S.A. - Cellular Biomedicine Group, Inc. - Ceronco Biosciences - Constellation Pharmaceuticals, Inc. - Cyclacel Pharmaceuticals, Inc. - Daiichi Sankyo Company, Limited - DiNonA Inc. - Effimune SAS - Eli Lilly and Company - Epirus Biopharmaceuticals, Inc. - EpiZyme, Inc. - Erytech Pharma SA - Eureka Therapeutics, Inc. - Fate Therapeutics, Inc. - Formula Pharmaceuticals, Inc. - Gamida Cell Ltd. - GlaxoSmithKline Plc - Hangzhou Minsheng Pharmaceutical Group Co.,Ltd For more information visit http://www.researchandmarkets.com/research/tr...ymphocytic
FATE: 1.75 (-0.02), AMGN: 160.18 (-0.92), EPZM: 10.35 (+0.04), LLY: 79.14 (-0.52), ATRA: 22.67 (-0.50), GSK: 43.52 (+0.14), BMY: 75.39 (+0.11), ATNM: 1.79 (unch), CYCC: 5.00 (-0.02), BLCM: 14.23 (-0.73), BPTH: 1.79 (unch), CALA: 3.45 (-0.18), ABBV: 64.35 (+0.19), BXLT: 46.02 (-0.18), CBMG: 14.49 (+0.78)
Fate Therapeutics to Present at Leerink Partners 5th Annual Global Healthcare Conference
GlobeNewswire - Wed Feb 03, 3:01PM CST
Fate Therapeutics, Inc. (NASDAQ:FATE), a biopharmaceutical company dedicated to the development of programmed cellular immunotherapeutics for cancer and immune disorders, announced today that Scott Wolchko, President and Chief Executive Officer, will be presenting a company overview at the Leerink Partners 5 Annual Global Healthcare Conference on Wednesday, February 10, 2016 at 1:25 p.m. ET in New York City.
FATE: 1.75 (-0.02)
Biotech Sector Report; Potential Rebound for These Four Biotech Securities
ACCESSWIRE - Mon Feb 01, 7:01AM CST
NEW YORK, NY / ACCESSWIRE / February 1, 2016 / MannKind Corporation (NASDAQ: MNKD), Fate Therapeutics Inc. (NASDAQ: FATE), Raptor Pharmaceutical Corp. (NASDAQ: RPTP), and Zafgen Inc. (NASDAQ: ZFGN) are four tickers in the biotech space currently suffering due to the overall poor market sentiment towards the space. The biotech sector has had a cruel start to the year. The Nasdaq Biotechnology Index is down 18% so far in 2016, and is now off about 30% since its July peak. This fall in market value has led to potential opportunities for big players in the space to pick up valuable assets are very low prices. While large drugmakers have hardly been exempt from the pain, the selloff should present a chance for them to find some cheap deals.
ZFGN: 6.92 (+0.31), FATE: 1.75 (-0.02), RPTP: 5.89 (-0.05), MNKD: 1.14 (-0.03)
Exelixis's Cabozantinib Granted Priority Review in the U.S.
Zacks Equity Research - Zacks Investment Research - Fri Jan 29, 3:20PM CST
Exelixis (EXEL) announced that both the FDA and EMA have accepted its NDA and MAA, respectively, for cabozantinib, for the treatment of advanced RCC.
FATE: 1.75 (-0.02), ANIK: 52.79 (-0.51), ARRY: 3.74 (+0.03), EXEL: 8.15 (unch)
Fate's (FATE) ProTmune Gets Fast Track Status, Stock Up
Zacks Equity Research - Zacks Investment Research - Tue Jun 21, 10:46AM CDT
Fate Therapeutics (FATE) announced that the FDA has granted the Fast Track status to its immunotherapy ProTmune.
FATE: 1.75 (-0.02), ANIP: 55.38 (-1.13), RTRX: 18.47 (-0.18), ACOR: 25.57 (-0.64)
Fate Therapeutics (FATE) Catches Eye: Stock Jumps 19.1%
Zacks Equity Research - Zacks Investment Research - Tue Jun 21, 7:25AM CDT
Fate Therapeutics, Inc. (FATE) moved big last session, as its shares jumped over 19% on the day.
FATE: 1.75 (-0.02), NEO: 8.92 (-0.23)
Fate Therapeutics to Host Off-the-Shelf Cancer Immunotherapy Focus Session at 2016 Annual Meeting of International Society for Stem Cell Research
GlobeNewswire - Thu Jun 16, 7:01AM CDT
Fate Therapeutics, Inc. (NASDAQ:FATE), a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that it will host a Focus Session entitled "Fighting Cancer with Off-the-Shelf iPSC Immunotherapies" at the 2016 Annual Meeting of the International Society for Stem Cell Research (ISSCR) on Wednesday, June 22, 2016 from 9:00 a.m. to 12:00 p.m. PT in San Francisco, California.
FATE: 1.75 (-0.02)
Fate Therapeutics Appoints Chris M. Storgard, M.D. as Chief Medical Officer
GlobeNewswire - Tue May 17, 7:01AM CDT
Fate Therapeutics, Inc. (NASDAQ:FATE), a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, today announced that Chris M. Storgard, M.D. has joined the Company as its Chief Medical Officer. Dr. Storgard is an experienced drug development clinician with a proven history of advancing early stage programs through clinical development and product commercialization. As CMO, he will lead the design and execution of the Company's clinical trials for its programmed cellular immunotherapies.
FATE: 1.75 (-0.02)
Fate Therapeutics reports 1Q loss
Automated Insights - Mon May 09, 4:12PM CDT
SAN DIEGO (AP) _ Fate Therapeutics Inc. (FATE) on Monday reported a loss of $8.4 million in its first quarter.
FATE: 1.75 (-0.02)
Fate Therapeutics Reports First Quarter 2016 Financial Results
GlobeNewswire - Mon May 09, 3:01PM CDT
Phase 1/2 Clinical Trial of ProTmune(TM) for Prevention of Acute GvHD and CMV Infection to Begin Enrollment in mid-2016
FATE: 1.75 (-0.02)
Tissue Engineering Market To Reach $11.53 Billion By 2022 Owing To Increased Focus Of Stem Cell Therapies: Grand View Research, Inc.
GlobeNewswire - Thu May 05, 4:00AM CDT
Global tissue engineering market is expected to reach USD 11.53 billion by 2022, according to a new report by Grand View Research, Inc. The demand for tissue engineering is expected to upsurge owing to the shift of focus from stem cell therapies to immunocelluar therapies. Moreover, companies such as Caladrius and Celyad changed their names from Cardio3 Bio NeoStem respectively to reflect their focus on immunotherapies.
FATE: 1.75 (-0.02)
Fate Therapeutics to Webcast Conference Call Reporting First Quarter 2016 Financial Results on May 9, 2016
GlobeNewswire - Mon May 02, 3:01PM CDT
Fate Therapeutics, Inc. (NASDAQ:FATE), a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that the Company will host a conference call and live audio webcast on Monday, May 9, 2016 at 5:00 p.m. ET to report its first quarter 2016 financial results and provide a corporate update.
FATE: 1.75 (-0.02)
Fate Therapeutics (FATE) Jumps: Stock Moves 6.5% Higher
Zacks Equity Research - Zacks Investment Research - Mon Apr 11, 7:15AM CDT
Fate Therapeutics, Inc. (FATE) shares rose almost 7% in the last trading session.
FATE: 1.75 (-0.02), ANIK: 52.79 (-0.51)
Fate Therapeutics to Present at the Needham & Company 15th Annual Healthcare Conference
GlobeNewswire - Tue Apr 05, 3:01PM CDT
Fate Therapeutics, Inc. (NASDAQ:FATE), a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that Scott Wolchko, President and Chief Executive Officer, will be presenting a company overview at the Needham & Company 15th Annual Healthcare Conference in New York City on Tuesday, April 12, 2016 at 4:20 p.m. ET.
FATE: 1.75 (-0.02)
Fate Therapeutics Reports Fourth Quarter and Full Year 2015 Financial Results
GlobeNewswire - Thu Mar 03, 3:01PM CST
ProTmune(TM) Investigational New Drug Application for Prevention of Acute GvHD and CMV Infection Cleared by FDA in January 2016
FATE: 1.75 (-0.02)
Vertex (VRTX) Down on CRL for Kalydeco Label Expansion
Arpita Dutt - Zacks Investment Research - Mon Feb 08, 4:38PM CST
The FDA informed Vertex (VRTX) that its sNDA for expanding the label of its CF treatment, Kalydeco, cannot be approved in its present form.
FATE: 1.75 (-0.02), VRTX: 90.10 (+1.14), LGND: 126.76 (+0.90), CELG: 103.41 (-1.62)
Novo Nordisk Posts In Line Q4 Earnings, Tops Revenues
Zacks Equity Research - Zacks Investment Research - Thu Feb 04, 12:40PM CST
Novo Nordisk (NVO) reported fourth quarter 2015 revenues that increased 2.3% year over year to $4.2 billion beating Zacks Consensus Estimate of $4.1 billion.
FATE: 1.75 (-0.02), NVO: 55.36 (+0.80), ATRA: 22.67 (-0.50), BXLT: 46.02 (-0.18)
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Pipeline Review, H2 2015
M2 - Thu Feb 04, 5:02AM CST
Research and Markets (http://www.researchandmarkets.com/research/trfcb9/acute_lymphocytic) has announced the addition of the "Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Overview - Therapeutics Development - Pipeline Products for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Overview - Pipeline Products for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Comparative Analysis - Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Therapeutics under Development by Companies - Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Therapeutics under Investigation by Universities/Institutes - Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Products under Development by Companies - Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Products under Investigation by Universities/Institutes - Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Companies Involved in Therapeutics Development Companies Mentioned - Partial List - 4SC AG - AbbVie Inc. - Actinium Pharmaceuticals, Inc. - Affimed Therapeutics AG - Altor BioScience Corporation - Amgen Inc. - Atara Biotherapeutics, Inc. - Baxalta Incorporated - Bellicum Pharmaceuticals, Inc. - Bexion Pharmaceuticals, LLC. - Bio-Path Holdings, Inc. - BioSight Ltd. - Bristol-Myers Squibb Company - Calithera Biosciences, Inc. - Cantargia AB - Celator Pharmaceuticals, Inc. - Cellectis S.A. - Cellular Biomedicine Group, Inc. - Ceronco Biosciences - Constellation Pharmaceuticals, Inc. - Cyclacel Pharmaceuticals, Inc. - Daiichi Sankyo Company, Limited - DiNonA Inc. - Effimune SAS - Eli Lilly and Company - Epirus Biopharmaceuticals, Inc. - EpiZyme, Inc. - Erytech Pharma SA - Eureka Therapeutics, Inc. - Fate Therapeutics, Inc. - Formula Pharmaceuticals, Inc. - Gamida Cell Ltd. - GlaxoSmithKline Plc - Hangzhou Minsheng Pharmaceutical Group Co.,Ltd For more information visit http://www.researchandmarkets.com/research/tr...ymphocytic
FATE: 1.75 (-0.02), AMGN: 160.18 (-0.92), EPZM: 10.35 (+0.04), LLY: 79.14 (-0.52), ATRA: 22.67 (-0.50), GSK: 43.52 (+0.14), BMY: 75.39 (+0.11), ATNM: 1.79 (unch), CYCC: 5.00 (-0.02), BLCM: 14.23 (-0.73), BPTH: 1.79 (unch), CALA: 3.45 (-0.18), ABBV: 64.35 (+0.19), BXLT: 46.02 (-0.18), CBMG: 14.49 (+0.78)
Fate Therapeutics to Present at Leerink Partners 5th Annual Global Healthcare Conference
GlobeNewswire - Wed Feb 03, 3:01PM CST
Fate Therapeutics, Inc. (NASDAQ:FATE), a biopharmaceutical company dedicated to the development of programmed cellular immunotherapeutics for cancer and immune disorders, announced today that Scott Wolchko, President and Chief Executive Officer, will be presenting a company overview at the Leerink Partners 5 Annual Global Healthcare Conference on Wednesday, February 10, 2016 at 1:25 p.m. ET in New York City.
FATE: 1.75 (-0.02)
Biotech Sector Report; Potential Rebound for These Four Biotech Securities
ACCESSWIRE - Mon Feb 01, 7:01AM CST
NEW YORK, NY / ACCESSWIRE / February 1, 2016 / MannKind Corporation (NASDAQ: MNKD), Fate Therapeutics Inc. (NASDAQ: FATE), Raptor Pharmaceutical Corp. (NASDAQ: RPTP), and Zafgen Inc. (NASDAQ: ZFGN) are four tickers in the biotech space currently suffering due to the overall poor market sentiment towards the space. The biotech sector has had a cruel start to the year. The Nasdaq Biotechnology Index is down 18% so far in 2016, and is now off about 30% since its July peak. This fall in market value has led to potential opportunities for big players in the space to pick up valuable assets are very low prices. While large drugmakers have hardly been exempt from the pain, the selloff should present a chance for them to find some cheap deals.
ZFGN: 6.92 (+0.31), FATE: 1.75 (-0.02), RPTP: 5.89 (-0.05), MNKD: 1.14 (-0.03)
Exelixis's Cabozantinib Granted Priority Review in the U.S.
Zacks Equity Research - Zacks Investment Research - Fri Jan 29, 3:20PM CST
Exelixis (EXEL) announced that both the FDA and EMA have accepted its NDA and MAA, respectively, for cabozantinib, for the treatment of advanced RCC.
FATE: 1.75 (-0.02), ANIK: 52.79 (-0.51), ARRY: 3.74 (+0.03), EXEL: 8.15 (unch)
